NCT02399566 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Status UNKNOWN Phase PHASE4
NCT02186847 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT02121925 Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up Status TERMINATED Phase N/A
NCT02093000 A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma Status COMPLETED Phase N/A
NCT02011997 Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Status UNKNOWN Phase PHASE3
NCT01942629 Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas Status UNKNOWN Phase N/A
NCT01737502 Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT01578668 Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Status COMPLETED Phase PHASE2
NCT01578551 Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Status TERMINATED Phase PHASE2
NCT01482585 Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy Status UNKNOWN Phase N/A
NCT01386385 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT01294306 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Status COMPLETED Phase PHASE2
NCT01249066 Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma Status UNKNOWN Phase N/A
NCT01249053 Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma Status UNKNOWN Phase N/A
NCT00955305 Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer Status TERMINATED Phase PHASE2
NCT00950365 Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT00716456 Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib Status COMPLETED Phase PHASE1/PHASE2
NCT00334815 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Status ACTIVE_NOT_RECRUITING Phase PHASE2